Work

Abstract CT197: A first-in-human (FIH), phase 1/2, dose-escalation, dose-optimization, and dose-expansion study of PARP1-selective inhibitor EIK1003 as monotherapy and in combination in patients with advanced solid tumors

Year: 2025

Type: conference-abstract

Source: Cancer Research

DOI: 10.1158/1538-7445.am2025-ct197

Authors: Gerald Falchook, Drew Rasco, Jian Zhang, Yongsheng Li, Jianqing Zhu, Joohyuk Sohn, Christina Teng, Bernard Doger, Chih-Yi Hsieh, Caroline Taromino, Yawei Zhang, Viola J. Chen, Guru Sonpavde

Institutions: HealthONE, South Texas Accelerated Research Therapeutics, Fudan University Shanghai Cancer Center, Chongqing Cancer Hospital, Zhejiang Cancer Hospital, Severance Hospital, Hospital Universitario Fundación Jiménez Díaz, IMPACT Therapeutics (China), AdventHealth Orlando

Language: English

Topic: PARP inhibition in cancer therapy

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4409823123

Cites:

Cited by:

Related to: 10